Literature DB >> 18662339

Divergent phosphorylation pattern of tau in P301L tau transgenic mice.

Natasha Deters1, Lars M Ittner, Jürgen Götz.   

Abstract

Aggregates of hyperphosphorylated tau are prominent in brains of patients with Alzheimer's disease or frontotemporal dementia (FTD). They have been reproduced in animal models following the identification of tau mutations in familial cases of FTD. This includes our previously generated transgenic model, pR5, which expresses FTD (P301L) mutant tau in neurons. The mice are characterized by tau aggregation including tangle (NFT) formation, memory impairment and mitochondrial dysfunction. In 8-month-old mice, S422 phosphorylation of tau is linked to NFT formation, however, a detailed analysis of tau solubility, phosphorylation and aggregation has not been done nor have the mice been monitored until a high age. Here, we undertook an analysis by immunohistochemistry, Gallyas impregnation and Western blotting of brains from 3 month- up to 20 month-old mice. NFTs first appeared at 6 months in the amygdala, followed by the CA1 region of the hippocampus. As the mice get older, the solubility of tau is decreased as determined by sequential extractions. Histological analysis revealed increased phosphorylation at the AT180, AT270 and 12E8 epitopes with ageing. The numbers of AT8-positive neurons increased from 3 to 6 months old. However, whereas S422 appeared only late and concomitantly with NFT formation, the only neurons left with AT8-reactivity at 20 months were those that had undergone NFT formation. As hyperphosphorylated tau continued to accumulate, the lack of AT8-reactivity suggests regulatory mechanisms in specifically dephosphorylating the AT8 epitope in the remaining neurons. Thus, differential regulation of phosphorylation is important for NFT formation in neurodegenerative diseases with tau pathology.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18662339     DOI: 10.1111/j.1460-9568.2008.06318.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  39 in total

1.  Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach.

Authors:  Laetitia Troquier; Raphaelle Caillierez; Sylvie Burnouf; Francisco J Fernandez-Gomez; Marie-Eve Grosjean; Nadege Zommer; Nicolas Sergeant; Susanna Schraen-Maschke; David Blum; Luc Buee
Journal:  Curr Alzheimer Res       Date:  2012-05       Impact factor: 3.498

2.  Novel screening cascade identifies MKK4 as key kinase regulating Tau phosphorylation at Ser422.

Authors:  Fiona Grueninger; Bernd Bohrmann; Klaus Christensen; Martin Graf; Doris Roth; Christian Czech
Journal:  Mol Cell Biochem       Date:  2011-06-03       Impact factor: 3.396

3.  In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice.

Authors:  Kaoru Yamada; John R Cirrito; Floy R Stewart; Hong Jiang; Mary Beth Finn; Brandon B Holmes; Lester I Binder; Eva-Maria Mandelkow; Marc I Diamond; Virginia M-Y Lee; David M Holtzman
Journal:  J Neurosci       Date:  2011-09-14       Impact factor: 6.167

4.  Spatial Training Ameliorates Long-Term Alzheimer's Disease-Like Pathological Deficits by Reducing NLRP3 Inflammasomes in PR5 Mice.

Authors:  Qing-Guo Ren; Wei-Gang Gong; Hong Zhou; Hao Shu; Yan-Juan Wang; Zhi-Jun Zhang
Journal:  Neurotherapeutics       Date:  2019-04       Impact factor: 7.620

5.  Nicotinamide forestalls pathology and cognitive decline in Alzheimer mice: evidence for improved neuronal bioenergetics and autophagy procession.

Authors:  Dong Liu; Michael Pitta; Haiyang Jiang; Jong-Hwan Lee; Guofeng Zhang; Xinzhi Chen; Elisa M Kawamoto; Mark P Mattson
Journal:  Neurobiol Aging       Date:  2012-12-25       Impact factor: 4.673

Review 6.  Convergence of amyloid-beta and tau pathologies on mitochondria in vivo.

Authors:  Anne Eckert; Kathrin L Schulz; Virginie Rhein; Jürgen Götz
Journal:  Mol Neurobiol       Date:  2010-03-09       Impact factor: 5.590

7.  Oligomeric and fibrillar species of beta-amyloid (A beta 42) both impair mitochondrial function in P301L tau transgenic mice.

Authors:  Anne Eckert; Susanne Hauptmann; Isabel Scherping; Jessica Meinhardt; Virginie Rhein; Stefan Dröse; Ulrich Brandt; Marcus Fändrich; Walter E Müller; Jürgen Götz
Journal:  J Mol Med (Berl)       Date:  2008-08-16       Impact factor: 4.599

8.  An update on the toxicity of Abeta in Alzheimer's disease.

Authors:  Jürgen Götz; Lars M Ittner; Nicole Schonrock; Roberto Cappai
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

9.  Animal models for Alzheimer's disease and frontotemporal dementia: a perspective.

Authors:  Jürgen Götz; Naeman N Götz
Journal:  ASN Neuro       Date:  2009-11-09       Impact factor: 4.146

10.  Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease.

Authors:  Yazi D Ke; Fabien Delerue; Amadeus Gladbach; Jürgen Götz; Lars M Ittner
Journal:  PLoS One       Date:  2009-11-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.